BERKELEY, Calif., Jan. 20, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) is updating its 2008 revenue guidance range to $65 to $70 million. This increase is based on higher than expected utilization of manufacturing capacity, additional work under the fully funded Novartis collaboration and increased royalty payments as discussed below. With this information, the Company is able to provide additional guidance that it expects its cash, cash equivalents and short-term investments at the end of 2008 to be approximately the same as reported at the end of the third quarter of 2008.
